Gossamer Bio, Inc., a clinical-stage biopharmaceutical company based in San Diego, is making waves in the medical community with its groundbreaking approach to discovering, acquiring, developing, and commercializing therapeutics that focus on the disease areas of immunology, inflammation, and oncology in the United States. With an impressive pipeline of potential treatments, Gossamer Bio, Inc. is at the forefront of developing innovative solutions for a diverse range of conditions. One of its most promising developments is GB002, an inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor designed for the treatment of pulmonary arterial hypertension. Additionally, the company is working on GB004, a gut-targeted, oral small molecule that could revolutionize the treatment of inflammatory bowel disease. They are also developing GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase, and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. Gossamer Bio, Inc.'s commitment to providing effective treatments for various health conditions has not gone unnoticed. The company has established license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds, and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. Overall, Gossamer Bio, Inc. is a force to be reckoned with and clearly has its sights set on making a significant impact on the medical field.
Gossamer Bio, Inc.'s ticker is GOSS
The company's shares trade on the NASDAQ stock exchange
They are based in San Diego, California
There are 51-200 employees working at Gossamer Bio, Inc.
It is http://www.gossamerbio.com/
Gossamer Bio, Inc. is in the Healthcare sector
Gossamer Bio, Inc. is in the Biotechnology industry
The following five companies are Gossamer Bio, Inc.'s industry peers: